Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You keep adding two zeros to the size every time you post bid/ask. I think you're using Fidelity or TD, I've seen people using those services do that before. Whatever you're looking at, remove two and you'll have the actual.
You can look here to confirm:
https://www.otcmarkets.com/stock/NWBO/quote
Also, 95% of the volume is hitting the ask so far today. I will post each day on my twitter feed so we can see how these next 4 weeks go. The past few days are there already.
I only get one post per day so good luck to the longs today.
Agreed! I only get one post per day so wasn't able to tell ATL thank you yesterday! This is undoubtedly a big deal no matter what the usual suspects say. Too bad they don't understand exactly what they're looking at. Of course they think they do because they know everything.
Two filings last night in the Chardan case:
https://www.pacermonitor.com/public/case/21771510/Chardan_Capital_Markets,_LLC_v_Northwest_Biotherapeutics,_Inc
Hopefully Barcode or another person with access can post them.
Actually it’s not as unlikely as you make it sound.
58.1% of Ph3 go on to NDA/BLA submission.
Of those, 85.3% are approved.
https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf
They are late prints from regular hours hitting after close. Dark pool trades, for instance, don't need to hit the tape right away and can report later. Also, the market makers can swap shares between themselves after hours.
Barcode,
There is an update on the Yonemura case. You're the only person I'm aware of with a Pacer login. Would you be so kind to check it out and see if there's anything of substance?
Yonemura v Powers
PR About the Lawsuits
New Official PR about Lawsuits
NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
2017-10-25 13:47:03.685 GMT
NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
3 Cases Substantially Completed, 4th Case Pending Completion,
No Monetary Damages Contemplated
PR Newswire
BETHESDA, Md., Oct. 25, 2017
BETHESDA, Md., Oct. 25, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc.
(OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings.
Northwest Biotherapeutics Logo. (PRNewsFoto/Northwest Biotherapeutics, Inc.)
All four of the lawsuits have been or are being resolved without any negative findings against the Company or its management, despite allegations of misconduct and misrepresentation, and resolved without any monetary damages. One of the cases was dismissed outright, in its entirety, by the court. Two further cases were settled after NW Bio announced the Nasdaq remediation plan on September 6, 2016 and agreed to take certain future actions to enhance its corporate governance practices. The fourth case is in the process of being settled on similar terms, with a settlement agreement having been entered into and currently under review by a court.
From the outset, the Company has disputed the allegations made in the cases, and expressed an intention to vigorously defend the cases. The cases are summarized below.
Lerner v. Northwest Biotherapeutics, Inc.
Lerner v. Northwest Biotherapeutics, Inc. was filed on August 26, 2015, as a class action securities fraud lawsuit against NW Bio and its CEO in the U.S.
District Court for the District of Maryland making a variety of claims about purportedly false reporting about the results of the DCVax-Direct Phase I trial and the DCVax-L Phase III GBM trial, among other things. On March 21, 2017, the court granted NW Bio's motion to dismiss the Complaint in its entirety, with an extensive opinion that included the following conclusion: "Upon review of the pleadings, arguments, and relevant case law, the Court finds that Plaintiffs have failed to establish an actionable misrepresentation or omission."
Every claim was dismissed. On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired. This action is over.
Tharp, et al. v. Cognate, et al.
Tharp, et al. v. Cognate, et al. was filed on June 19, 2015, in the Delaware Court of Chancery challenging transactions between NW Bio and Cognate and the Toucan entities. This was a class action and derivative lawsuit purportedly on behalf of the Company and its shareholders naming Cognate, various Toucan entities, and NW Bio's Board of Directors as defendants and seeking disgorgement of purportedly improper benefits and an unspecified amount of damages, among other relief. After extensive litigation and negotiations, and the Nasdaq remediation plan announced by NW Bio on September 6, 2016, a settlement was reached with mutual releases of any liability, and NW Bio's agreement to adopt several expanded corporate governance practices and policies, and no payment of monetary settlement consideration.
This settlement was approved by the court on October 17, 2017 and this case is over.
Yonemura v. Powers, et al.
Yonemura v. Powers, et al. was filed on November 19, 2015, in Maryland federal court as yet another derivative action very similar to the Tharp case described above. The Yonemura plaintiff joined in the settlement with Tharp and committed to release all of her claims as well.
As a result, the plaintiff has agreed to dismiss the Yonemura case in the near future.
Wells v. Powers, et al.
Wells v. Powers, et al. was filed on November 28, 2016, in the Circuit Court for Montgomery County Maryland. The allegations in this case copy the derivative claims filed by the plaintiffs in Tharp and Yonemura, and tack on additional derivative claims that appear to echo the now-dismissed allegations in the Lerner case. The parties have reached a settlement similar to Tharp and Yonemura, with mutual releases, the Company agreeing to adopt several expanded corporate governance practices and policies, and no payment of monetary settlement consideration.
On October 12, 2017, the plaintiff submitted the settlement to the Court for preliminary approval. The parties are now awaiting the decision on the preliminary approval motion.
Conclusion
Company CEO Linda Powers stated "lawsuits like these can be a distraction from the important work of companies like ours. In my opinion, disposing of these cases is an important step forward in our vindication from the relentless and false campaign to discredit our science, our operations and our ethics, and hopefully helps remove what have been delaying obstacles in our path forward. These resolutions come with no further price tag to shareholders, allowing us to focus our resources on the Company's mission of providing our promising vaccines to as many solid tumor cancer patients as possible, at the earliest time possible."
I haven't been keeping up with the board so apologies if this was covered. From the 10k (I bolded 2 parts as to why I am posting this section). Also, I don't have permission to reply until tomorrow.
1.
Organization and Description of Business
Northwest Biotherapeutics, Inc. and its wholly owned subsidiaries NW Bio Gmbh, and Aracaris Capital, Ltd (collectively, the “Company”, “we”, “us” and “our”) were organized to discover and develop innovative immunotherapies for cancer.
The Company is developing an experimental dendritic cell vaccine using its platform technology known as DCVax. DCVax is currently being tested for use in the treatment of certain types of cancers.
Cognate BioServices, Inc. (“Cognate BioServices”), which is a company related by common ownership (Note 9), provides the Company with mission critical contract manufacturing services, research and development services, distribution and logistics, and related services, in compliance with the Company’s specifications and the applicable regulatory requirements for clinical grade cellular products. The Company and Cognate BioServices are currently parties to a series of contracts providing for these services as more fully described below. The Company is dependent on Cognate BioServices to provide the manufacturing services, and any interruption of such services could potentially have a material adverse effect on the Company’s ability to proceed with its clinical trials. Cognate BioServices’ manufacturing facility for clinical-grade cellular products is located in Memphis, Tennessee. In addition, a Cognate affiliate in Germany works with the Fraunhofer Institute to produce DCVax-L products there, and Cognate affiliates in the UK and Israel are preparing for production of DCVax-L products in those locations.
Although there are many contract manufacturers for small molecule drugs and for biologics, there are only a few contract manufacturers in the U.S., and even fewer in Europe, that specialize in producing living cell products and that have a track record of success with regulatory authorities. The manufacturing of living cell products is highly specialized and entirely different than production of biologics: the physical facilities and equipment are different, the types of personnel and skill sets are different, and the processes are different. The regulatory requirements relating to manufacturing and cellular products are especially challenging and are one of the most frequent reasons for the development of a company’s cellular products to be put on clinical hold (i.e., stopped by regulatory authorities).
In addition, the Company’s programs require a large amount of capacity in these specialized manufacturing facilities, and require that the large capacity be dedicated exclusively to the Company’s programs. Most medical products, including cellular products, are made in standardized batches: the same manufacturing suites are used for a number of companies’ products, at designated times scheduled in advance. In contrast, the Company’s products are fully personalized and not made in standardized batches: the Company’s products are made on demand, patient by patient, on an as needed basis.
I have the whole presentation downloaded to my PC
I highly doubt this 10k will affect the price at all. Nothing will move it now except dilutions and/or PH3 data...and right when I click to post the message, here comes the AF article to try to make that happen. So maybe it will after all. Who cares anymore anyway? It's either a sunk cost or a future unexpected happy ending.
Sure thing, Maxim
Intracoastal
Basin, to your reply, I think so (i'm only allowed one post per day).
1:15 in 2007
1:16 in 2012
if history repeats itself, this is the year
You need to talk to Stillwell
I highlighted what I thought was the most important part Here.
Hey JD, how come when the stock was $12 the longs hadn't won but now that it's 23 cents the shorts have? It ain't over yet big boy.
PGSD-
I believe it was you the other day asking about my strategy at work. I apologize about not getting back, I've been restricted to one post per day due to my actions.
NWBO is not in it. It's a value strategy of positions over $1 billion MC and much more stable.
Anyway, after reading your post I am happy you found something to solidify your thesis here. I would just issue a word of caution to not underestimate the power of wall street. If their intentions are to not let NWBO succeed like Doc thinks is possible, investing more is a tremendous risk no matter what NWBO has. Just look at where we are now. None of us longtimers would ever have imagined this. There's no telling when it will stop, if ever.
Good luck.
In response to Flippers post#111476 - they aren't.
In response to Sub_Atomic - HI! haha
These are guys accused and fined by the SEC for fraud and they are buying and selling shares of NWBO. Now exwannabe will crawl out from under his rock and tell us how there is nothing nefarious going on with any stocks.
DLNY - Delaney Equity Group - on Level 3 this morning.
https://www.sec.gov/litigation/litreleases/2015/lr23384.htm
Bull case: they cut a deal with these shorts to give them time to get out and now the stock can finally move upward
Bear case: now NWBO can string this failure along for another 61 days and have a reason to give bulls as to why they aren't talking
Does this page (projects tab) appear different to anyone? I was last on it on March 5th. I believe it is worded differently. My cache does not go back that far.
http://www.izi.fraunhofer.de/en/departments/leipzig-location/therapy-validation.html
From my B/D's short locate system
Securities to Locate
Security NWBO
Avail. Qty 1,435,234
Rate(%)* -16.943
Please post again so we're clear on what you're saying.
Well once again, I am on your side on that front. Fwiw, I liked sguesaldi better.
I have expressed my concerns about getting whoever KCG is shorting for off their throats before or at the same time as announcing results because I fear they will just suppress the price with more relentless naked shorting. All the "they will have to cover" talk doesn't work for me. Once you are doing something illegal you don't change your mind and roll it back because data has changed.
I am relying on Cofer Black to make that happen.
No he didn't. Try to find that 500k share trade at 3:32:30 by Merrill. You won't. He was on the advertisements not trade recap. I know because I sit on a Bloomberg all day and it says so right in the top right of his screen shot.
Chow posted indications of interest and adverts, not trades.
If you go to GP <go> and add chart content "current shares outstanding" it shows the 154M has been since end of December...so this year's financings are missing. If you want to be really depressed, switch it to a 5 year chart.
No I am not on Facebook. You can email me here:
Tctrader38@gmail.com
Then I will reply from my personal email after I get your address.
Can you privately get me your email address in any way? Twitter PM me or if you talk to any of the regular long-timers privately, they probably have my contact info.
no update yet
Good luck GoodGuy. Can't blame you.
(PRN) NW BIO Announces Registered Direct Offering Of $7.5 Millio n
+------------------------------------------------------------------------------+
NW BIO Announces Registered Direct Offering Of $7.5 Million
2017-03-17 13:00:10.902 GMT
NW BIO Announces Registered Direct Offering Of $7.5 Million
PR Newswire
BETHESDA, Md., March 17, 2017
BETHESDA, Md., March 17, 2017 /PRNewswire/ -- Northwest Biotherapeutics
(OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $7.5 million.
In the transaction, the Company will sell approximately 28.8 million shares of common stock at a purchase price of $0.26 per share, or pre-funded warrants in lieu of shares. Additionally, the investors will receive five year Class A warrants to purchase up to approximately 21.6 million shares of common stock with an exercise price of $0.26 per share. They also will receive three month Class B warrants to purchase up to approximately 21.6 million shares of common stock with an exercise price of $1.00 per share. Finally, in lieu of shares, to the extent required to prevent the beneficial ownership of an investor, together with affiliates, of our Common Stock from exceeding 4.99%, investors will receive pre-funded Class C warrants which are exercisable immediately. The exercise price of these Class C warrants will also be $0.26 per share, with $0.25 per share pre-funded at the time of closing and another $0.01 per share payable upon exercise of each Class C Warrant.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as the exclusive placement agent for the transaction. The placement is expected to close on or about March 22, 2017, subject to satisfaction of customary closing conditions.
The securities described above are being offered pursuant to a shelf registration statement (File No. 333-213777), which was declared effective by the United States Securities and Exchange Commission ("SEC") on October 18, 2016. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by request at H.C. Wainwright & Co. at placements@hcwco.com.
It is business as usual today. They are the hammer.
Virtu Financial bids to buy Knight Capital Group. Hope they consider all the BS naked shorts they hold.
no update on the website
https://www.pacermonitor.com/public/case/9970453/Yonemura_v_Powers_et_al
Lots of volume and first notice for me of BMAK